WASHINGTON -- From extended-release tablets to foam-based formulas to authorized genelics, the generic drug industry continues to introduce a variety of products.
For example, Lupin Pharmaceuticals Inc. has received final approval from the Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for tramadol hydrochloride extended-release tablets in 100-, 200- and 300-mg strengths
Tramadol HCI ER is a centrally acting synthetic analgesic in an extended-release formulation and is the generic equivalent to Ortho-McNeil's Ultram ER tablets. It is indicated for the management of moderate to moderately severe chronic pain in adults who require …
No comments:
Post a Comment